Synopsis
Synopsis
0
EU WC
0
VMF
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Akamin
2. Akne Puren
3. Akne-puren
4. Aknemin
5. Aknin Mino
6. Aknin-mino
7. Aknosan
8. Apo Minocycline
9. Apo-minocycline
10. Arestin
11. Blemix
12. Cyclomin
13. Cyclops
14. Dentomycin
15. Dynacin
16. Hydrochloride, Minocycline
17. Icht Oral
18. Icht-oral
19. Klinomycin
20. Lederderm
21. Mestacine
22. Minakne
23. Mino Wolff
24. Mino-wolff
25. Minocin
26. Minocin Mr
27. Minoclir
28. Minocycline
29. Minocycline Monohydrochloride
30. Minocycline, (4r-(4 Alpha,4a Beta,5a Beta,12a Beta))-isomer
31. Minolis
32. Minomycin
33. Minoplus
34. Minotab
35. Minox 50
36. Monohydrochloride, Minocycline
37. Mynocine
1. 13614-98-7
2. Minocycline Hcl
3. Arestin
4. Solodyn
5. Minomycin
6. Minocin
7. Dynacin
8. Periocline
9. Ximino
10. Minocycline (hydrochloride)
11. Vectrin
12. Minomax
13. (4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide Hydrochloride
14. Mynocine Hydrochloride
15. Minocycline (as Hydrochloride)
16. Minocycline, Hydrochloride
17. 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide Monohydrochloride
18. 0020414e5u
19. Tri-mino
20. Nsc-141993
21. Dsstox_cid_24545
22. Dsstox_rid_80306
23. Dsstox_gsid_44545
24. (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydrochloride
25. [4s-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide Monohydrochloride
26. Lederderm
27. Mynocine
28. Acnez
29. Minomycin Chloride
30. Chebi:50697
31. (4s-(4alpha,4aalpha,5aalpha,12aalpha))-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide Monohydrochloride
32. [4s-(4?,4a?,5a?,12a?)]-4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
33. 2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, Hydrochloride (1:2), (4s,4as,5ar,12as)-
34. Einecs 237-099-7
35. Minocycline Hydrochloride (internal Use)
36. C23h27n3o7.hcl
37. Minocycline, Hcl
38. Unii-0020414e5u
39. Ncgc00096006-01
40. Prestwick_626
41. Arestin (tn)
42. Dynacin (tn)
43. Minocin (tn)
44. Solodyn (tn)
45. Minocycline Hydrochloride [usp:jan]
46. 7-dimethylamino-6-demethyl-6-deoxytetracycline, Hcl
47. Mfcd00083669
48. Minocyclinhydrochlorid
49. Amzeeq
50. Minolira
51. Zilxi
52. Minomycin Hydrochloride
53. Schembl2537
54. Cas-13614-98-7
55. 2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, Monohydrochloride, (4s-(4alpha,4aalpha,5aalpha,12aalpha))-
56. Mls002548863
57. Spectrum1500414
58. Fxfm-244
59. Chembl1200881
60. Chembl4576719
61. Dtxsid8044545
62. Hms1568p12
63. Pharmakon1600-01500414
64. Bcp06597
65. Tox21_111250
66. Tox21_113183
67. Tox21_301590
68. Ccg-40107
69. Nsc757120
70. S4226
71. Minocycline Hydrochloride [mi]
72. Minocycline Hydrochloride, Crystalline
73. Akos015951312
74. Minocycline Hydrochloride (jp17/usp)
75. Tox21_111250_1
76. Cs-1256
77. Minocycline Hydrochloride [jan]
78. Nc00460
79. Nsc-757120
80. Minocycline Hydrochloride [mart.]
81. Minocycline Hydrochloride [vandf]
82. Ncgc00178854-03
83. Ncgc00255988-01
84. Ac-22362
85. As-75306
86. Hy-17412
87. Minocycline Hydrochloride [usp-rs]
88. Minocycline Hydrochloride [who-dd]
89. Smr001906766
90. M2288
91. D00850
92. Minocycline Hydrochloride [orange Book]
93. Minocycline Hydrochloride [usp Monograph]
94. 614m987
95. Sr-01000075625
96. Q-201407
97. Sr-01000075625-1
98. Q27104777
99. Minocycline Hydrochloride, Antibiotic For Culture Media Use Only
100. Minocycline Hydrochloride, European Pharmacopoeia (ep) Reference Standard
101. Minocycline Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
102. Minocycline Hydrochloride, United States Pharmacopeia (usp) Reference Standard
103. (4s,12as,4as,5ar)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide Hydrochloride
104. (4s,4as,5ar,12as)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamidehydrochloride
105. 2-naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, Monohydrochloride, (4s-(4.alpha.,4a.alpha.,5a.alpha.,12a.alpha.))-
Molecular Weight | 493.9 g/mol |
---|---|
Molecular Formula | C23H28ClN3O7 |
Hydrogen Bond Donor Count | 6 |
Hydrogen Bond Acceptor Count | 9 |
Rotatable Bond Count | 3 |
Exact Mass | 493.1615779 g/mol |
Monoisotopic Mass | 493.1615779 g/mol |
Topological Polar Surface Area | 165 Ų |
Heavy Atom Count | 34 |
Formal Charge | 0 |
Complexity | 971 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 4 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 10 | |
---|---|
Drug Name | Arestin |
PubMed Health | Minocycline |
Drug Classes | Amebicide, Intestinal, Antiacne, Antiacne Antibacterial, Antibiotic, Antiprotozoal, Tetracycline |
Drug Label | ARESTIN (minocycline hydrochloride) Microspheres is a subgingival sustained-release product containing the antibiotic minocycline hydrochloride incorporated into a bioresorbable polymer, Poly (glycolide-co-dl-lactide) or PGLA, for professional subg... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Powder, extended release |
Route | Dental |
Strength | eq 1mg base |
Market Status | Prescription |
Company | Orapharma |
2 of 10 | |
---|---|
Drug Name | Dynacin |
Drug Label | Minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2naphthacenecarboxamide monohydrochloride. Its structural formula is:C23H27N3O7... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 75mg base |
Market Status | Prescription |
Company | Cnty Line Pharms |
3 of 10 | |
---|---|
Drug Name | Minocin |
PubMed Health | Minocycline, Regular Release (By mouth) |
Drug Classes | Amebicide, Intestinal, Antiacne, Antibiotic, Antiprotozoal |
Drug Label | MINOCIN minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride.Its structural formula is:C23H27N... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Capsule; Injectable |
Route | Injection; Oral |
Strength | eq 100mg base; eq 50mg base; eq 100mg base/vial |
Market Status | Prescription |
Company | Rempex Pharms; Precision Dermat |
4 of 10 | |
---|---|
Drug Name | Minocycline hydrochloride |
Drug Label | To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are pr... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Capsule |
Route | oral; Oral |
Strength | 65mg; 115mg; eq 100mg base; eq 50mg base; eq 105mg base; eq 65mg base; eq 115mg base; eq 75mg base; eq 90mg base; eq 80mg base; 55mg; eq 45mg base; eq 55mg base; eq 135mg base |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Ranbaxy; Teva; Mylan Labs; Sun Pharm Inds; Aurobindo Pharma; Lupin; Barr Labs; Sandoz; Par Pharm; Watson Labs; Ranbaxy Labs; Dr Reddys Labs; Impax Labs |
5 of 10 | |
---|---|
Drug Name | Solodyn |
PubMed Health | Minocycline |
Drug Classes | Amebicide, Intestinal, Antiacne, Antiacne Antibacterial, Antibiotic, Antiprotozoal, Tetracycline |
Drug Label | Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [4S-(4,4a,5a,12a)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono hydrochloride. The structura... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 105mg base; eq 65mg base; eq 115mg base; eq 80mg base; eq 55mg base |
Market Status | Prescription |
Company | Medicis |
6 of 10 | |
---|---|
Drug Name | Arestin |
PubMed Health | Minocycline |
Drug Classes | Amebicide, Intestinal, Antiacne, Antiacne Antibacterial, Antibiotic, Antiprotozoal, Tetracycline |
Drug Label | ARESTIN (minocycline hydrochloride) Microspheres is a subgingival sustained-release product containing the antibiotic minocycline hydrochloride incorporated into a bioresorbable polymer, Poly (glycolide-co-dl-lactide) or PGLA, for professional subg... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Powder, extended release |
Route | Dental |
Strength | eq 1mg base |
Market Status | Prescription |
Company | Orapharma |
7 of 10 | |
---|---|
Drug Name | Dynacin |
Drug Label | Minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1, 11-dioxo-2naphthacenecarboxamide monohydrochloride. Its structural formula is:C23H27N3O7... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Capsule |
Route | Oral |
Strength | eq 100mg base; eq 75mg base |
Market Status | Prescription |
Company | Cnty Line Pharms |
8 of 10 | |
---|---|
Drug Name | Minocin |
PubMed Health | Minocycline, Regular Release (By mouth) |
Drug Classes | Amebicide, Intestinal, Antiacne, Antibiotic, Antiprotozoal |
Drug Label | MINOCIN minocycline hydrochloride, is a semisynthetic derivative of tetracycline, 4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride.Its structural formula is:C23H27N... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Capsule; Injectable |
Route | Injection; Oral |
Strength | eq 100mg base; eq 50mg base; eq 100mg base/vial |
Market Status | Prescription |
Company | Rempex Pharms; Precision Dermat |
9 of 10 | |
---|---|
Drug Name | Minocycline hydrochloride |
Drug Label | To reduce the development of drug-resistant bacteria and maintain the effectiveness of minocycline hydrochloride capsules and other antibacterial drugs, minocycline hydrochloride capsules should be used only to treat or prevent infections that are pr... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Tablet, extended release; Tablet; Capsule |
Route | oral; Oral |
Strength | 65mg; 115mg; eq 100mg base; eq 50mg base; eq 105mg base; eq 65mg base; eq 115mg base; eq 75mg base; eq 90mg base; eq 80mg base; 55mg; eq 45mg base; eq 55mg base; eq 135mg base |
Market Status | Tentative Approval; Prescription |
Company | Mylan Pharms; Ranbaxy; Teva; Mylan Labs; Sun Pharm Inds; Aurobindo Pharma; Lupin; Barr Labs; Sandoz; Par Pharm; Watson Labs; Ranbaxy Labs; Dr Reddys Labs; Impax Labs |
10 of 10 | |
---|---|
Drug Name | Solodyn |
PubMed Health | Minocycline |
Drug Classes | Amebicide, Intestinal, Antiacne, Antiacne Antibacterial, Antibiotic, Antiprotozoal, Tetracycline |
Drug Label | Minocycline hydrochloride, a semi synthetic derivative of tetracycline, is [4S-(4,4a,5a,12a)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide mono hydrochloride. The structura... |
Active Ingredient | Minocycline hydrochloride |
Dosage Form | Tablet, extended release |
Route | Oral |
Strength | eq 105mg base; eq 65mg base; eq 115mg base; eq 80mg base; eq 55mg base |
Market Status | Prescription |
Company | Medicis |
Anti-Bacterial Agents
Substances that inhibit the growth or reproduction of BACTERIA. (See all compounds classified as Anti-Bacterial Agents.)
GDUFA
DMF Review : Reviewed
Rev. Date : 2013-07-02
Pay. Date : 2013-06-20
DMF Number : 13758
Submission : 1998-09-01
Status : Active
Type : II
Certificate Number : R1-CEP 1999-002 - Rev 06
Issue Date : 2022-12-02
Type : Chemical
Substance Number : 1030
Status : Valid
Registration Number : 304MF10123
Registrant's Address : Rua da Estacao, 1 e 1A, 2600-726 Castanheira do Ribatejo, Portugal
Initial Date of Registration : 2022-08-17
Latest Date of Registration : --
NDC Package Code : 17158-0900
Start Marketing Date : 2017-03-07
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Samo Pharmaceutical Co., Ltd.
Registration Date : 2024-01-31
Registration Number : 20240131-211-J-1572
Manufacturer Name : CIPAN - Companhia Industrial Produtora de Antibióticos, SA
Manufacturer Address : Rua da Estação, 1/1A, 2600-726 Castanheira do Ribatejo, Portugal
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 2408
Submission : 1975-02-26
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13404
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 7849
Submission : 1989-01-04
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13755
Submission : 1998-09-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15171
Submission : 2000-12-01
Status : Inactive
Type : II
Certificate Number : R1-CEP 1998-152 - Rev 02
Issue Date : 2009-12-11
Type : Chemical
Substance Number : 1030
Status : Valid
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 13748
Submission : 1998-09-01
Status : Inactive
Type : II
Certificate Number : R0-CEP 1999-072 - Rev 02
Issue Date : 2004-08-20
Type : Chemical
Substance Number : 1030
Status : Withdrawn by Holder
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 26050
Submission : 2012-07-20
Status : Active
Type : II
NDC Package Code : 58623-0133
Start Marketing Date : 2019-09-04
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 15014
Submission : 2000-10-02
Status : Active
Type : II
GDUFA
DMF Review : Reviewed
Rev. Date : 2019-05-10
Pay. Date : 2018-07-25
DMF Number : 32664
Submission : 2018-05-14
Status : Active
Type : II
NDC Package Code : 73402-112
Start Marketing Date : 2021-06-08
End Marketing Date : 2024-12-31
Dosage Form (Strength) : POWDER (1kg/kg)
Marketing Category : BULK INGREDIENT
Registrant Name : Ace Biopharm Co., Ltd.
Registration Date : 2022-09-05
Registration Number : 20220905-211-J-1355
Manufacturer Name : Zhejiang Changhai Pharmaceuticals Co.,Ltd.
Manufacturer Address : 188 Mid Zhiyuan Avenue, Binhai New Area, Shaoxing City, Zhejiang Province, 312366, PRChina
Registration Number : 304MF10123
Registrant's Address : Rua da Estacao, 1 e 1A, 2600-726 Castanheira do Ribatejo, Portugal
Initial Date of Registration : 2022-08-17
Latest Date of Registration : 2022-08-17
Registration Number : 217MF10699
Registrant's Address : Via del Vecchio Politecnico n. 9, 20121 Milano (MI) - Italy
Initial Date of Registration : 2005-10-07
Latest Date of Registration : 2020-01-31
Registration Number : 219MF10124
Registrant's Address : Sete Casas 2674-506 Loures PORTUGAL
Initial Date of Registration : 2007-04-18
Latest Date of Registration : 2017-12-06
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 21, 2024
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharma Hits Key Goals in Phase 3 Trial of Mino-Lok Antibiotic Lock Solution
Details : Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Product Name : Mino-Lok
Product Type : Small molecule
Upfront Cash : Not Applicable
May 21, 2024
Details:
DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 18, 2024
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated for the treatmen...
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
March 18, 2024
Details:
The funding will support the anticipated expenses for DFD-29 (minocycline hydrochloride), being developed for the treatment of rosacea, including an upcoming New Drug Application submission and preparation for its potential commercial launch.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: SWK Holdings
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Financing January 02, 2024
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : SWK Holdings
Deal Size : Undisclosed
Deal Type : Financing
Journey Medical Corporation Secures Credit Facility with SWK Holdings for up to $20 Million
Details : The funding will support the anticipated expenses for DFD-29 (minocycline hydrochloride), being developed for the treatment of rosacea, including an upcoming New Drug Application submission and preparation for ...
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Undisclosed
January 02, 2024
Details:
Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 02, 2024
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Trial of its Mino-Lok® Therapeutic...
Details : Mino-Lok (MLT) is a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Product Name : Mino-Lok
Product Type : Small molecule
Upfront Cash : Not Applicable
January 02, 2024
Details:
DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated in phase 3 trials for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Dr. Reddy\'s Laboratories
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 05, 2023
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Dr. Reddy\'s Laboratories
Deal Size : Not Applicable
Deal Type : Not Applicable
Journey Medical Corporation Submits New Drug Application to FDA for DFD-29 to Treat Rosacea
Details : DFD-29 (minocycline hydrochloride) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is being evaluated in phase 3 trial...
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
December 05, 2023
Details:
Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo RM
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Berkeley Biologics
Deal Size: $35.0 million Upfront Cash: $35.0 million
Deal Type: Divestment November 09, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and ...
Product Name : CanGaroo RM
Product Type : Small molecule
Upfront Cash : $35.0 million
November 09, 2023
Details:
DFD-29 (minocycline hydrochloride modified release capsules) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is currently being investigated for the treatment of papulopustular rosacea.
Lead Product(s): Minocycline Hydrochloride
Therapeutic Area: Dermatology Product Name: DFD-29
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 20, 2023
Lead Product(s) : Minocycline Hydrochloride
Therapeutic Area : Dermatology
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : DFD-29 (minocycline hydrochloride modified release capsules) has anti-inflammatory properties independent of their antibacterial activity that correlate with certain aspects of the pathophysiology. It is curren...
Product Name : DFD-29
Product Type : Small molecule
Upfront Cash : Not Applicable
October 20, 2023
Details:
The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: HighCape Capital
Deal Size: $26.2 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 19, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : HighCape Capital
Deal Size : $26.2 million
Deal Type : Private Placement
Elutia Announces Private Placement for Proceeds up to $26 Million
Details : The net proceeds will support the Company’s advancement of its drug-eluting biomatrix products, including CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibioti...
Product Name : CanGaroo
Product Type : Small molecule
Upfront Cash : Undisclosed
September 19, 2023
Details:
Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and minocycline for extended antibiotic protection.
Lead Product(s): Rifampicin,Minocycline Hydrochloride
Therapeutic Area: Infections and Infectious Diseases Product Name: CanGaroo
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Berkeley Biologics
Deal Size: $35.0 million Upfront Cash: $35.0 million
Deal Type: Divestment September 18, 2023
Lead Product(s) : Rifampicin,Minocycline Hydrochloride
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Preclinical
Partner/Sponsor/Collaborator : Berkeley Biologics
Deal Size : $35.0 million
Deal Type : Divestment
Elutia Announces Sale of Orthobiologics Business Unit for Cash Proceeds of up to $35 Million
Details : Through the divestment, Elutia sells its Orthobiologics business unit to Berkeley Biologics, including Company’s lead drug-eluting product, CanGaroo featuring an advanced biomatrix and the drugs rifampin and ...
Product Name : CanGaroo
Product Type : Small molecule
Upfront Cash : $35.0 million
September 18, 2023
Details:
Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Lead Product(s): Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area: Infections and Infectious Diseases Product Name: Mino-Lok
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 10, 2023
Lead Product(s) : Minocycline Hydrochloride,Edetate Calcium Disodium,Ethanol
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : The University of Texas MD Anderson Cancer Center
Deal Size : Not Applicable
Deal Type : Not Applicable
Citius Pharmaceuticals Reaches 92 Event Milestone in Mino-Lok® Phase 3 Trial
Details : Mino-Lok (MLT), a novel antibiotic lock therapy that combines minocycline with edetate disodium, which is investigated for the treatment of patients with catheter-related blood stream infections.
Product Name : Mino-Lok
Product Type : Small molecule
Upfront Cash : Not Applicable
August 10, 2023
CAS Number : 127-33-3
End Use API : Minocycline Hydrochloride
About The Company : Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceuti...
Dibenzyl azodicarboxylate (DBAD)
CAS Number : 2449-05-0
End Use API : Minocycline Hydrochloride
About The Company : Haorui, established in 1997, is a manufacturer and supplier of APIs, intermediates, veterinary and food additives. Meanwhile, it is assisting global pharmaceuti...
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 50MG BASE
Approval Date : 2003-04-16
Application Number : 65131
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 75MG BASE
Approval Date : 2003-04-16
Application Number : 65131
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 100MG BASE
Approval Date : 2003-04-16
Application Number : 65131
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 115MG BASE
Approval Date : 2018-03-16
Application Number : 204453
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : Yes
TE Code :
Brand Name : SOLODYN
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 45MG BASE **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons**
Approval Date : 2006-05-08
Application Number : 50808
RX/OTC/DISCN : DISCN
RLD : Yes
TE Code :
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 65MG BASE
Approval Date : 2022-10-07
Application Number : 204394
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 75MG BASE
Approval Date : 2016-01-29
Application Number : 90217
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : CAPSULE;ORAL
Dosage Strength : EQ 50MG BASE
Approval Date : 2013-05-13
Application Number : 90867
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
RLD : No
TE Code :
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET, EXTENDED RELEASE;ORAL
Dosage Strength : EQ 105MG BASE
Approval Date : 2014-09-25
Application Number : 91118
RX/OTC/DISCN : DISCN
RLD : No
TE Code :
RLD : No
TE Code : AB
Brand Name : MINOCYCLINE HYDROCHLORIDE
Dosage Form : TABLET;ORAL
Dosage Strength : EQ 50MG BASE
Approval Date : 2004-01-06
Application Number : 65156
RX/OTC/DISCN : RX
RLD : No
TE Code : AB
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
Patent Expiration Date : 2025-06-24
US Patent Number : 8268804
Drug Substance Claim :
Drug Product Claim :
Application Number : 50808
Patent Use Code : U-1078
Delist Requested :
Patent Use Description : TREATMENT OF ACNE
Patent Expiration Date : 2025-06-24
Patent Expiration Date : 2025-06-24
US Patent Number : 7790705
Drug Substance Claim :
Drug Product Claim :
Application Number : 50808
Patent Use Code : U-1078
Delist Requested :
Patent Use Description : TREATMENT OF ACNE
Patent Expiration Date : 2025-06-24
Patent Expiration Date : 2025-06-24
US Patent Number : 8722650
Drug Substance Claim :
Drug Product Claim :
Application Number : 50808
Patent Use Code : U-1078
Delist Requested :
Patent Use Description : TREATMENT OF ACNE
Patent Expiration Date : 2025-06-24
Patent Expiration Date : 2025-06-24
US Patent Number : 8268804
Drug Substance Claim :
Drug Product Claim :
Application Number : 50808
Patent Use Code : U-1078
Delist Requested :
Patent Use Description : TREATMENT OF ACNE
Patent Expiration Date : 2025-06-24
Patent Expiration Date : 2025-06-24
US Patent Number : 8252776
Drug Substance Claim :
Drug Product Claim :
Application Number : 50808
Patent Use Code : U-124
Delist Requested :
Patent Use Description : TREATMENT OF ACNE
Patent Expiration Date : 2025-06-24
Patent Expiration Date : 2025-06-24
US Patent Number : 8268804
Drug Substance Claim :
Drug Product Claim :
Application Number : 50808
Patent Use Code : U-1078
Delist Requested :
Patent Use Description : TREATMENT OF ACNE
Patent Expiration Date : 2025-06-24
Patent Expiration Date : 2025-06-24
US Patent Number : 8252776
Drug Substance Claim :
Drug Product Claim :
Application Number : 201922
Patent Use Code : U-124
Delist Requested :
Patent Use Description : TREATMENT OF ACNE
Patent Expiration Date : 2025-06-24
Patent Expiration Date : 2030-10-01
US Patent Number : 10946101
Drug Substance Claim :
Drug Product Claim :
Application Number : 213690
Patent Use Code : U-1631
Delist Requested :
Patent Use Description : TREATMENT OF INFLAMMAT...
Patent Expiration Date : 2030-10-01
Patent Expiration Date : 2025-06-24
US Patent Number : 8268804
Drug Substance Claim :
Drug Product Claim :
Application Number : 201922
Patent Use Code : U-124
Delist Requested :
Patent Use Description : TREATMENT OF ACNE
Patent Expiration Date : 2025-06-24
Patent Expiration Date : 2011-07-05
Date Granted : 1994-07-05
Brand Name : ARESTIN MICROSPHERES
Patent Number : 1330533
Filing Date : 1988-05-24
Strength per Unit : 1mg/4mg Cartridge
Dosage Form : Extended Release Powder
Human Or VET : Human
Route of Administration : Sub Gingival
Patent Expiration Date : 2011-07-05
Date Granted : 1994-07-05
Patent Expiration Date : 2009-12-20
Date Granted :
Brand Name :
Patent Number : 2006105
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2009-12-20
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
Patent Expiration Date : 2009-12-20
Date Granted :
Brand Name :
Patent Number : 2006106
Filing Date :
Strength per Unit :
Dosage Form :
Human Or VET :
Route of Administration :
Patent Expiration Date : 2009-12-20
Date Granted :
Portfolio PDF
Product Web Link
Virtual Booth
Digital Content
Website
Corporate PDF
REF. STANDARDS & IMPURITIES
ANALYTICAL
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?